NCT04932967

Use of nMoABs for the Treatment of COVID-19 in Patients With HM.

Use of Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Patients With Hematological Malignancies (SIE-GIMEMA Study)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 91 (actual)
• Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter retrospective, non-interventional observational study to evaluate the efficacy of nMoAbs in HM patients.

Detailed description

This is a multicenter retrospective, non-interventional observational study. The participating centres will retrospectively review all episodes of SARS-CoV-2 infection occurring in HMs identified at their institutions from February 2020 to May 2021 and treated with nMoAbs, to evaluate their efficacy.

Conditions

• Covid19
• Hematological Malignancy

Timeline

• Start date: 2021-09-30
• Primary completion: 2022-04-11
• Completion: 2022-04-11
• First posted: 2021-06-21
• Last updated: 2022-06-22

Locations

14 sites across 1 country: Italy